Amylyx Reports Significantly Reduced Net Loss, Extended Cash Runway, and Pivotal Phase 3 Trial Completion
AMLX has more than doubled off its 52-week low of $2.6.
Summary
Amylyx Pharmaceuticals reported a significantly reduced net loss for 2025, extended its cash runway into 2028, and announced the completion of recruitment for its pivotal Phase 3 LUCIDITY trial with topline data expected in Q3 2026.
Key Events · Earnings and Guidance · AMLX
-
Strong Financial Performance
The company reported a net loss of $144.7 million for the year ended December 31, 2025, a significant reduction from $301.7 million in 2024. Net loss per share also improved to $1.53 from $4.43.
-
Extended Cash Runway
Cash, cash equivalents, and short-term investments totaled $317.0 million at December 31, 2025, with the company expecting its cash runway to fund operations into 2028.
-
Pivotal Phase 3 Trial Recruitment Complete
Recruitment for the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH) is complete, with topline data anticipated in Q3 2026. Avexitide holds FDA Breakthrough Therapy Designation for PBH.
-
Pipeline Advancement
Amylyx announced the selection of AMX0318, a novel GLP-1 receptor antagonist, as a development candidate for PBH and other rare diseases, targeting an IND filing in 2027. Early safety and tolerability data from Cohort 1 of the Phase 1 LUMINA trial for AMX0114 in ALS were also positive.
Analysis · AMLX · Life Sciences
This 8-K, furnishing the Q4 and full-year 2025 earnings press release, highlights significant positive developments for Amylyx Pharmaceuticals. While the financial results were also reported in a concurrent 10-K filing, this press release provides comprehensive details. Financially, the company reported a substantially reduced net loss for 2025 and extended its cash runway into 2028, providing a solid financial foundation. Operationally, the completion of recruitment for the pivotal Phase 3 LUCIDITY trial for avexitide (a Breakthrough Therapy Designated candidate for PBH) is a critical milestone, setting up a major catalyst with topline data expected in Q3 2026. Additionally, the selection of a new development candidate (AMX0318) and positive early safety data for AMX0114 demonstrate pipeline progression. These combined factors de-risk the company's near-term financial position and advance its key clinical programs, which could significantly impact future revenue potential.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.6% of the 1569 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMLX was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $2.60 to $17.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.